Effects of vascular endothelial cell growth factor on fibrovascular ingrowth into rabbit’s hydroxyapatite orbital implant

Abstract

The effects of different concentrations of vascular endothelial cell growth factor (VEGF) on the fibrovascular ingrowth into rabbits hydroxyapatite orbital implant were investigated. Twelve New Zealand white rabbits were divided into 3 groups and received hydroxyapatite orbital implant surgery in their right eyes. Before and after the operation, the implants were treated with 10 ng/ml VEGF, 100 ng/ml VEGF, or normal saline as control group. The animals received technetium bones scan at 2, 4, and 6 weeks postoperatively. The mean radioactivity counts within region of interest (ROI) of the surgery eye (R) and the non-surgery eye (L) in the same animal were tested, and the R/L ratios were calculated. The implants were harvested at 6th weeks and examined histopathologically. The results showed that at second week, there was no significant difference in mean R/L ratios between VEGF group and control group (F=2.83,P=0.111); At 4th week (F=7.728,P=0.011) and 6th week (F=7.831,P=0.011) postoperatively, the mean ratios in VEGF groups were significantly higher than that in control group. At 6th week postoperatively, the fibrovascularization rates in VEGF groups were higher than in control group significantly (F=8.711,P=0.008). It was suggested that VEGF could promote the fibrovascular ingrowth into hydroxyapatite orbital implant, thus might shorten the time required for complete vascularization of the HA orbital implant.

Keywords

vascular endothelial cell growth factor / hydroxyapatite / orbital implants / vascularization

References

[1] BuettnerH, BartleyG B. Tissue breakdown and exposure associated with orbital hydroxyapatite implants. Am J Ophthalmol, 1992, 113669-669

[2] ShieldsC L, ShieldsJ A, De PotterP, et al. . Problems with the hydroxyapatite orbital implant: implant. Ophthal Plast Resconstr Sur, 1996, 1218-18

[3] GoldbergR A, HoldsJ B, EbrahimpourJ. Exposed hydroxyapatite orbital implants: report of six cases. Ophthalmology, 1992, 99(5): 831-831

[4] FerraraN, Davis-SmythT. The biology of vascular endothelial growth factor. Endocr Rev, 1997, 18(1): 4-4

[5] KimI, RyanA M, RohanR, et al. . Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci, 1999, 402115-2115

[6] HobsonM I, GreenC J, TerenghiG, et al. . VEGF enhances intraneural angiogenesis and improves nerve regeneration after axotomy. J Anat, 2000, 197591-591

[7] AmanoS, RobanR, KutokiM, et al. . Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci, 1998, 3918-18

[8] KinghtonD R, HuntT K, ScheuenstuhlH, et al. . Oxygen tension regulates the expression of angiogenesis factor by macrophages. Science, 1983, 2211283-1283

[9] PachecoE M, CiveledA C, NatarajanT K, et al. . Clinicopathological correlation of technetium bone scan in vascularization of hydroxyapatite implants. A primate model. Arch Ophthalmol, 1997, 115(9): 1173-1173

[10] CivelekA C, PachecoE M, NatarajanT K, et al. . Quantitative measurement of vascularization and vascular ingrowth rate of coralline hydroxyapatite ocular implant by Tc-99m MDP bone imaging. Clin Nucl Med, 1995, 20(9): 779-779